Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03944577 · ClinicalTrials.gov registry record · Phase 2
Impact of Evolocumab in Cardiac Transplant Patients With CAV
A Phase 2 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03944577 is a Phase 2 study that has completed, run by University of Nebraska. The registered enrollment target is 26 participants.
The verdict
NCT03944577, a Phase 2 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
Coronary allograft vasculopathy (CAV) is diffusely accelerated atherosclerosis of a transplanted heart. Evolocumab (Repatha) is an FDA-approved drug for lowering low density lipoprotein (LDL) in patients who have not received a heart transplant. This drug works as a PCSK9-inhibitor. The primary objective of this study is to measure the impact of PCSK9-inhibitors on serum LDL in heart transplant patients with CAV after 12 weeks compared to baseline.
Interventions
- DRUG Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2023-03-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03944577
The ClinicalTrials.gov registry entry for NCT03944577 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Evolocumab is the first listed.
NCT03944577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03944577 about?
NCT03944577 is a clinical study titled "Impact of Evolocumab in Cardiac Transplant Patients With CAV". Coronary allograft vasculopathy (CAV) is diffusely accelerated atherosclerosis of a transplanted heart. Evolocumab (Repatha) is an FDA-approved drug for lowering low density lipoprotein (LDL) in patients who have not received a heart transplant. This drug works as a PCSK9-inhibitor. The primary obje...
What is the current status of trial NCT03944577?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2019-07-15. Estimated completion is 2023-03-28.
What interventions are being tested in trial NCT03944577?
The interventions under investigation include: Evolocumab (DRUG).
Who is sponsoring clinical trial NCT03944577?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.